Using sensitivity equations for computing gradients of the FOCE and FOCEI approximations to the population likelihood Joachim AlmquistJacob LeanderMats Jirstrand Original Paper Open access 24 March 2015 Pages: 191 - 209
Improved precision of exposure–response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment Matts KågedalMats O. KarlssonAndrew C. Hooker Original Paper 20 March 2015 Pages: 211 - 224
Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment Leonid GibianskyMylène GiraudonMohamed A. Kamal Original Paper 29 March 2015 Pages: 225 - 236
Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study Irene-Ariadne KechagiaAristides Dokoumetzidis Original Paper 29 March 2015 Pages: 237 - 250
The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments Tarjinder SahotaMeindert DanhofOscar Della Pasqua Original Paper Open access 14 April 2015 Pages: 251 - 261
Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment Jonathan KnightsShashank Rohatagi Original Paper Open access 29 March 2015 Pages: 263 - 273
Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis Stephan BenayChristophe MeilleThierry Lave Original Paper 31 March 2015 Pages: 275 - 285
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects Mario González-SalesOlivier BarrièreMario Tanguay Original Paper 21 April 2015 Pages: 287 - 299
Reporting guidelines for population pharmacokinetic analyses Kevin DykstraNitin MehrotraWonkyung Byon Original Paper Open access 30 April 2015 Pages: 301 - 314
